

| Catalog No. | CY257020 |
|---|---|
| Description |
InVivoMAb Anti-Dog CD20/MS4A1 Antibody (Iv0177) [Iv0177] (CY257020) is a dog monoclonal antibody detecting B-lymphocyte surface antigen B1 in ELISA, Neutralization. Suitable for Dog.
|
| Species reactivity | Dog |
| Applications | ELISA, Neutralization |
| Host species | Canine |
| Isotype | IgG2, kappa |
| Clone ID | Iv0177 |
| Clonality | Monoclonal |
| Target | B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20 |
| Endotoxin level | Please contact with the lab for this information. |
| Purity | >95% as determined by SDS-PAGE. |
| Associated products | pH 7.4 Dilution Buffer |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | Q3C2E2 |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Background | B-lymphocyte antigen CD20 (MS4A1) is a ~33 kDa protein. B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. CD20 is the therapeutic target of rituximab (MabThera) and obinutuzumab (Gazyva). |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for InVivoMAb Anti-Dog CD20/MS4A1 Antibody (Iv0177).


Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com


+86-27-87433958
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский